JMS CO.,LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 534 JPY | +1.71% |
|
+2.69% | +6.16% |
| Sales 2022 | 58.17B 369M 30.78B | Sales 2023 | 63.74B 404M 33.73B | Capitalization | 12.79B 81.13M 6.77B |
|---|---|---|---|---|---|
| Net income 2022 | 826M 5.24M 437M | Net income 2023 | 281M 1.78M 149M | EV / Sales 2022 | 0.46 x |
| Net Debt 2022 | 11.9B 75.52M 6.3B | Net Debt 2023 | 13.42B 85.14M 7.1B | EV / Sales 2023 | 0.41 x |
| P/E ratio 2022 |
18
x | P/E ratio 2023 |
45.5
x | Employees | 5,650 |
| Yield 2022 |
2.79% | Yield 2023 |
3.25% | Free-Float | 66.09% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.71% | ||
| 1 week | +2.69% | ||
| Current month | -0.19% | ||
| 1 month | -0.19% | ||
| 3 months | +0.19% | ||
| 6 months | +0.95% | ||
| Current year | +6.16% |
1 week
518.00
534.00
1 month
511.00541.00
Current year
500.00548.00
1 year
489.00608.00
3 years
483.001 015.00
5 years
483.001 198.00
10 years
483.001 198.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hiroaki Okukubo
PSD | President | 68 | 01/78/01 |
Masafumi Sato
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/87/01 |
Masaki Endo
ADM | Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hiroaki Okukubo
PSD | President | 68 | 01/78/01 |
Yasuhiro Awane
BRD | Director/Board Member | 63 | 01/84/01 |
Masafumi Sato
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/87/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 31 M€ | +14.18% | ||
| 0.00% | 18 M€ | +16.15% | - | |
| 0.00% | 144,586 M€ | +16.91% | ||
| 0.00% | 66,066 M€ | +17.14% | - | |
| 0.00% | 20,721 M€ | +15.97% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 534 | +1.71% | 17 400 |
| 26/24/26 | 525 | +0.19% | 16,200 |
| 25/24/25 | 524 | 0.00% | 12,000 |
| 24/24/24 | 524 | +0.19% | 14,300 |
| 23/24/23 | 523 | +0.58% | 10,900 |
Delayed Quote Japan Exchange, April 30, 2024 at 11:30 am IST
More quotes
JMS CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of medical equipment and drugs. The Company operates through five geographical segments including Japan, Singapore, China, Philippines and Germany. The Company is engaged in the manufacture and sale of infusion and nutrition products, dialysis products, surgery products, blood and cell products and other products. The Companyâs main products include infusion & transfusion set, syringe pump, surgical gown, dialysis kit, peritoneal dialysate, microcatheter, blood bag, among others. The Company is also involved in the provision of maintenance service and other related services.
Calendar
14/05/2024
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +6.16% | 82.03M | |
| -3.37% | 186B | |
| -2.52% | 107B | |
| -3.93% | 67.44B | |
| +3.07% | 50.03B | |
| +16.42% | 47.81B | |
| +4.79% | 41.03B | |
| +1.57% | 26.85B | |
| +2.94% | 25.82B | |
| -0.38% | 25.01B |
- Stock Market
- Equities
- 7702 Stock
